Early-stage Breast Cancer Clinical Trial
— REaCT-RETTOfficial title:
A Pragmatic Randomised, Multicentre Trial Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)
Verified date | September 2022 |
Source | Ottawa Hospital Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
REaCT-RETT will demonstrate the non-inferiority of concurrent compared to sequential endocrine therapy in patients receiving post-operative radiotherapy for early stage breast cancer.
Status | Completed |
Enrollment | 262 |
Est. completion date | April 9, 2022 |
Est. primary completion date | June 9, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with newly diagnosed early stage, hormone receptor positive breast cancer - Planned to receive both endocrine therapy and post-operative radiotherapy - Able to provide verbal consent Exclusion Criteria: - Previous endocrine therapy for invasive breast cancer - Previous radiotherapy for breast cancer in the same breast |
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa Hospital Research Institute | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
Ottawa Hospital Research Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Endocrine toxicity | To measure endocrine toxicity. The Functional Assessment of Cancer Therapy - Endocrine Sub-scale (FACT-ES) is a questionnaire specific to patients with endocrine symptoms and measures the side effects and putative benefits of hormonal treatments given (endocrine therapy) in breast cancer. The FACT-ES questionnaire is comprised of 5 sections; physical well-being (7 questions), social/family well-being (7 questions), emotional well-being (6 questions), functional well-being (7 questions) and additional concerns (19 questions). A total of 46 questions are asked that all contain an answer on a scale range of 0-4, with 0 representing the answer 'not at all' and 4 representing the answer 'very much'. Of the 46 questions asked 31/46 have 'very much' representing the worst answer and the remaining 15/46 have 'very much' representing the best answer. | 12 months (+/- 2 weeks) post final fraction of radiotherapy | |
Secondary | Radiotherapy toxicity | To evaluate the acute and early-moderate late toxicities of radiotherapy in terms of skin toxicity, pneumonitis, and breast pain. This will be recorded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, with breast cosmesis recorded as per the European Organisation for Research and Treatment of Cancer (EORTC) cosmetic rating system for breast cancer. These standardized criteria have been used in a recent Canadian breast radiation randomized trial, RAPID, and the investigators will use a similar template to record any radiation toxicities at different points of time. | 12 months (+/- 2 weeks) post final fraction of radiotherapy | |
Secondary | Rates of starting endocrine therapy and compliance | Rates of starting endocrine therapy, compliance rates, discontinuation rates, along with the reasons for discontinuation. | 12 months (+/- 2 weeks) post final fraction of radiotherapy | |
Secondary | Direct Estimation of Health Utility Values | To measure the patient quality of life using the validated FACT-B questionnaire. The Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B) is a questionnaire that measures multidimensional quality of life in patients with breast cancer. The FACT-B questionnaire is comprised of 5 sections; physical well-being (7 questions), social/family well-being (7 questions), emotional well-being (6 questions), functional well-being (7 questions) and additional concerns (10 questions). A total of 37 questions are asked that all contain an answer on a scale range of 0-4, with 0 representing the answer 'not at all' and 4 representing the answer 'very much'. Of the 46 questions asked 20/37 have 'very much' representing the worst answer and the remaining 17/37 have 'very much' representing the best answer. | 12 months (+/- 2 weeks) post final fraction of radiotherapy | |
Secondary | Incremental cost-effectiveness ratios | Incremental cost-effectiveness ratios (cost per one quality-adjusted life year (QALY) gained and cost per one endocrine toxicity case averted) will be measured using the EQ-5D-5L questionnaire. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) questionnaire consists of two sections; the descriptive system and the visual analogue scale. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and has 5 levels associated with it (no problems, slight problems, moderate problems, severe problems and extreme problems). The scale range of 1-5 is used for the 5 dimensions where 1 is the best outcome and 5 is the worst outcome. The Visual Analogue scale records the respondent's self-rated health on a vertical, visual scale with endpoints labelled "the best health you can imagine" at the top and "the worst health you can imagine" at the bottom. This ranges 0-100 with 0 being the worst outcome and 100 being the best outcome. | 12 months (+/- 2 weeks) post final fraction of radiotherapy | |
Secondary | Exploratory analyses on evaluating radiotherapy toxicity | Exploratory analyses will be performed evaluating toxicity in patients receiving different types of radiotherapy (i.e. local versus regional radiotherapy). This will be evaluated using data collected on breast volume, seroma size, dose heterogeneity and the time of stimulation and planning. | 12 months (+/- 2 weeks) post final fraction of radiotherapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05528263 -
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
|
N/A | |
Completed |
NCT00165243 -
Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05559164 -
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
|
Phase 2 | |
Recruiting |
NCT04553770 -
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06001762 -
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03664687 -
Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
|
Phase 4 | |
Recruiting |
NCT04603209 -
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
|
||
Completed |
NCT00233077 -
Patient Centered Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT02958033 -
Shandong Cancer Hospital Affiliated to Shandong University
|
Phase 3 | |
Recruiting |
NCT03788083 -
Intratumoral TriMix Injections in Early Breast Cancer Patients
|
Phase 1 | |
Recruiting |
NCT03797248 -
Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer
|
||
Recruiting |
NCT05582499 -
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05871437 -
Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer
|
Phase 4 | |
Recruiting |
NCT04003558 -
Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01)
|
||
Terminated |
NCT03894007 -
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02982148 -
Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients
|
Phase 4 | |
Active, not recruiting |
NCT03553797 -
Accelerated Whole Breast Irradiation Hypofractionation Plus Boost VS Standard Whole Breast Irradiation Plus Boost
|
Phase 3 | |
Recruiting |
NCT06215469 -
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
|
N/A | |
Enrolling by invitation |
NCT06409221 -
VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study
|
||
Not yet recruiting |
NCT05280288 -
Effect of the App Bone@BC Version 4.0 Under the Follow-up for Patients With Early Breast Cancer
|
N/A |